Enlivex Therapeutics Ltd
NASDAQ:ENLV
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Price:
1.62 USD
Market Closed
Updated:
May 6, 2024
Enlivex Therapeutics Ltd
Net Income (Common)
|
Enlivex Therapeutics Ltd
Net Income (Common) Peer Comparison
Comparables:
CLGN
KMDA
URGN
ENTX
B
BONS
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Net Income (Common)
-$29.1m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Net Income (Common)
-$7m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Net Income (Common)
$8.3m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
34%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Net Income (Common)
-$102.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Net Income (Common)
-$8.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Net Income (Common)
-₪31m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-12%
|
See Also
What is Enlivex Therapeutics Ltd's Net Income (Common)?
Net Income (Common)
-29.1m
USD
-29.1m
USD
Based on the financial report for Dec 31, 2023, Enlivex Therapeutics Ltd's Net Income (Common) amounts to -29.1m USD.
What is Enlivex Therapeutics Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-69%
-69%
Over the last year, the Net Income (Common) growth was 6%. The average annual Net Income (Common) growth rates for Enlivex Therapeutics Ltd have been -35% over the past three years , -69% over the past five years .
You don't have any saved screeners yet
